Status:
RECRUITING
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Castrate Resistance Prostate Cancer
OligoProgressive Metastatic Disease
Eligibility:
MALE
18-100 years
Phase:
PHASE2
Brief Summary
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remainin...
Detailed Description
The current standard of care for patients with metastatic Oligopressive (OP) Castrate Resistance Prostate Cancer (CRPC) is a change in Systemic Therapy (ST). We propose that Stereotactic Body Radiothe...
Eligibility Criteria
Inclusion
- Age \>18 years
- Able to provide informed consent
- Histologic diagnosis of prostate adenocarcinoma
- Castrate Resistance Prostate Cancer
- Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions
- Receiving any line of ST for \>3 months
- All sites of OP disease are amenable to and can be safely treated with SBRT
- ECOG performance status 0-3
Exclusion
- Evidence of spinal cord compression
- Contraindication to radiotherapy
Key Trial Info
Start Date :
July 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2030
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06927635
Start Date
July 8 2025
End Date
June 1 2030
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9